Partner Therapeutics Names Ellen Hukkelhoven Ph.D. and Terry Gould to Board of Directors
12 March 2018 - - Boston-based cancer therapeutics developer Partner Therapeutics, Inc. (PTx) has appointed Dr. Ellen Hukkelhoven and Terry Gould to its board of directors, the company said.
They join the company's founders Bob Mulroy and Debasish Roychowdhury as directors.
Hukkelhoven is a senior analyst at healthcare investment firm Perceptive Advisors; she also serves on the board of MeiraGTx. She received her PhD in Cancer Biology from Memorial Sloan Kettering Cancer Center. Hukkelhoven graduated magna cum laude from Princeton University with degrees in Molecular Biology and Finance.
Gould is a partner and head of venture growth equity investments with Adams Street Partners. He invests in venture and growth-oriented companies with a focus on the healthcare space. He also sits on the board of directors of Aptinyx, Atox Bio, Corvus Pharmaceuticals, Fusion Pharmaceuticals, LifeBond, Orbus Therapeutics and Outpost Medicine.
PTx is an integrated commercial stage biotech company focused on the development and commercialisation of therapeutics that improve health and economic outcomes in the treatment of cancer.
Its development focus spans the entire range of cancer therapy from primary treatments to supportive care.